Ignite Creation Date:
2024-05-06 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 12:40 PM
Study NCT ID:
NCT03439046
Status:
COMPLETED
Last Update Posted:
2024-02-23
First Post:
2018-01-29
Brief Title:
Study of the Molecular Features of Postmenopausal Women With HR HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and in Patients With a PIK3CA Mutation on Second-line Treatment With Alpelisib Plus Fulvestrant
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Cancer |
Keywords:
| Name | View |
|---|---|
| BYL719 | View |
| HR-positive HER2-negative | View |
| advanced breast cancer | View |
| LEE011 | View |
| ribociclib | View |
| letrozole | View |
| CDK | View |
| CDK4 | View |
| CDK6 | View |
| CDK46 | View |
| Phase IIIb | View |
| ER-positive | View |
| PR-positive | View |
| postmenopausal | View |
| biomarker | View |
| ctDNA | View |
| liquid biopsy | View |
| PIK3CA | View |
| alpelisib | View |
| fulvestrant | View |